Aligning Investments in Therapeutic Development with Therapeutic Need Closing the Gap (2025) / Chapter Skim
Currently Skimming:


Pages 223-226

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 223...
... Mr. David Scheer was determined to have a conflict of interest in relation to service on the Committee on Strategies to Better Align Investments in Innovations for Therapeutic Development with Disease Burden and Unmet Needs based on his current role as advisor for Nektar Therapeutics and Twist Biosciences.
From page 225...
... we compared these pharmaceutical portfolios by GBD cause to the respective disease burden. The remaining sections in this document provide additional information about each of these steps.
From page 226...
... 226 ALIGNING INVESTMENTS IN THERAPEUTIC DEVELOPMENT Manual Mapping of Drug–Use Pairs to Create a Validation Dataset To assess and optimize the performance of the LLM-based mapping, we created a validation dataset from Pfizer and Sanofi's current and pipeline drug portfolios. Two independent coders mapped each drug–use pair to GBD causes, risk, and injury codes, with a third reviewer resolving any discrepancies.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.